Literature DB >> 8968979

Intraoperative maintenance of tissue perfusion prevents ARDS. Adult Respiratory Distress Syndrome.

D Thangathurai1, C Charbonnet, C C Wo, W C Shoemaker, M S Mikhail, P Roffey, P Roessler, K Kuchta, V Zelman, T R DeMeester, R Katz.   

Abstract

Patients undergoing prolonged, complex oncological surgery are at increased risk of developing the adult respiratory distress syndrome (ARDS) and other organ failures. Our hypothesis is that maintaining adequate tissue perfusion and oxygenation may prevent tissue hypoxia and acidosis in pulmonary, peripheral, and splanchnic microcirculations. Experimental evidence suggests that the hypoxic, acidotic endothelium stimulates the release of cytokines, kinins, and other mediators. We developed and tested an intraoperative protocol for surgical patients likely to develop ARDS and organ dysfunction; the protocol focuses on the intraoperative period but is not limited to this time. Nitroglycerin and fluids were used to maintain tissue perfusion and prevent tissue hypoxia as reflected by transcutaneous oxygen tension values. In 155 high-risk patients, none developed ARDS. We conclude that maintenance of tissue perfusion and oxygenation in high-risk surgical patients decreases the incidence of ARDS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968979

Source DB:  PubMed          Journal:  New Horiz        ISSN: 1063-7389


  2 in total

1.  Endpoints of resuscitation of critically injured patients: normal or supranormal? A prospective randomized trial.

Authors:  G C Velmahos; D Demetriades; W C Shoemaker; L S Chan; R Tatevossian; C C Wo; P Vassiliu; E E Cornwell; J A Murray; B Roth; H Belzberg; J A Asensio; T V Berne
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

2.  The use of regional cerebral oximetry monitoring during controlled hypotension: a case series.

Authors:  Brandon A Van Noord; Christopher L Stalker; Peter Roffey; Duraiyah Thangathurai
Journal:  J Clin Monit Comput       Date:  2013-10-18       Impact factor: 2.502

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.